Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Launched by DECIPHERA PHARMACEUTICALS, LLC · Jul 11, 2025

Keywords

ClinConnect Summary

This clinical study is looking at how people with Tenosynovial Giant Cell Tumor (TGCT), a rare joint condition, experience treatment with a medicine called vimseltinib in everyday life. The goal is to learn more about how this treatment is used outside of a hospital or research setting, including how it affects patients’ quality of life and their overall treatment experience. This study does not involve giving any new treatments or changing the care participants receive—it simply gathers information from medical records and patient feedback.

People who might join this study are those diagnosed with TGCT who have been prescribed vimseltinib either recently or are about to start it. To be eligible, participants should not have used other systemic treatments for TGCT in the past six months and should not be currently enrolled in another vimseltinib clinical trial. If someone joins, they can expect to share information about their health and treatment experience while continuing their regular care without any changes from the study team. This helps doctors understand how vimseltinib works in real life and how it impacts patients’ daily lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of TGCT according to medical records
• • 2. Prescribed vimseltinib per the approved label requirements. Participants are eligible if either (A) the decision to receive vimseltinib has been made but treatment has not yet been initiated or (B) the decision to receive vimseltinib has been made and participant has received first dose of prescribed vimseltinib less than 6 months prior to study enrollment
• • 3. Has provided informed consent and medical records release
• Exclusion Criteria:
• • 1. Participant has received any other systemic agent for the treatment of TGCT during the 6 months prior to starting treatment with vimseltinib
• • 2. Participant has received the first dose of prescribed vimseltinib in the current treatment course more than 6 months before study enrollment
• • 3. Participant is active in an interventional clinical trial of vimseltinib